Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK -positive NSCLC: Implications for disease assessment and management

<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma

Monika E. Hegi, Annie‐Claire Diserens, Thierry Gorlia et al. · New England Journal of Medicine · 2005 · 7.3K citations · Full text

Medicine, Molecular Biology, Oncology +17

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

Patrick Y. Wen, David R. Macdonald, David A. Reardon et al. · Journal of Clinical Oncology · 2010 · 3.8K citations · Full text

Medicine, Neurology, Oncology +15

<i>MGMT</i> Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

Alba A. Brandes, Enrico Franceschi, Alicia Tosoni et al. · Journal of Clinical Oncology · 2008 · 831 citations · Full text

Medicine, Oncology, Radiology +17

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

Shirish M. Gadgeel, Leena Gandhi, Gregory J. Riely et al. · The Lancet Oncology · 2014 · 695 citations

Medicine, Oncology, Pharmacology +16

Clinical Experience With Crizotinib in Patients With Advanced <i>ALK</i>-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

Daniel B. Costa, Alice T. Shaw, Sai‐Hong Ignatius Ou et al. · Journal of Clinical Oncology · 2015 · 605 citations · Full text

Medicine, Oncology, Pharmacology +14